# Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.

> **NCT04483856** · NA · COMPLETED · sponsor: **Relife Italia S.r.l.** · enrollment: 70 (actual)

## Conditions studied

- Radiodermatitis
- Dermatitis, Radiation-Induced

## Interventions

- **DEVICE:** DermoRelizema cream
- **DEVICE:** Dexeryl

## Key facts

- **NCT ID:** NCT04483856
- **Lead sponsor:** Relife Italia S.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2023-02-16
- **Final completion:** 2023-02-16
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483856, "Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04483856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*